Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Legend Biotech Corp.
Headquarters: Somerset, New Jersey, United States of America
Website: http://www.legendbiotech.com...
Year Founded: 2014
Status: Public
Industry Sector: HealthTechnology
CEO: Ying Huang, PhD
Number Of Employees: 2,609
Enterprise Value: $5,177,823,867
PE Ratio: -36.55
Exchange/Ticker 1: NASDAQ:LEGN
Exchange/Ticker 2: N/A
Latest Market Cap: $6,499,337,728
BioCentury | Jan 4, 2025
Management Tracks
Four companies announce new CFOs
Plus: Jia joins Grit Bio and Riley joins Avalo
BioCentury | Dec 11, 2024
Product Development
ROR1 shines as the next promising ADC target
Also in BioCentury’s Clinical Report: ASH readouts from Cardiff Oncology, Arcellx and GSK; plus data from NewAmsterdam, AbbVie and more
BioCentury | Nov 14, 2024
Data Byte
Cross-border trends in uncertain times for China biotech
A new start-up model and licensing deals fueled by new modalities sustain the momentum of China biotech’s innovation engine
BioCentury | Nov 14, 2024
Management Tracks
New CEOs at Valo, Apriori
Plus: Glasspool to lead VarmX, Novartis vet Eissa joins Cellares and updates from Mestag, Andera, Incyclix and more
BioCentury | Nov 8, 2024
Editor's Commentary
China biotech and the bear: a Perspective
Deal-making with the West offers a path through uncertain times, but in what position will China biotechs emerge from the bear?
BioCentury | Nov 6, 2024
Deals
Dealmaking in a drought crowns Gracell, Proteologix BayHelix winners
M&A and licensing deals feature prominently in nearly all categories of this year’s BayHelix Awards
BioCentury | Nov 5, 2024
Management Tracks
Alan Bash named president of Carvykti at Legend
Plus: CureVac hires Axel Malkomes as CFO; new CEOs at Coya, Libra; and updates from 4BIO, Memo and Alltrna
BioCentury | Oct 1, 2024
Product Development
BCMA CAR Ts diverge in early lines, as Carvykti dominates market
In BioCentury’s latest Clinical Report, AbbVie hits in Parkinson’s, plus data from Shattuck, Merck and Celldex
BioCentury | Jul 18, 2024
Politics, Policy & Law
A takeout could remove CAR T play Legend from Biosecure’s glare
The J&J partner, under scrutiny by House select committee, is said to be attracting M&A interest
BioCentury | Jun 4, 2024
Data Byte
House select committee’s expanded scope weighs on GenScript, Legend
Therapeutic developers now on China committee’s radar, not just CROs
Items per page:
1 - 10 of 112